Literature DB >> 3198298

Plasma protein binding of zolpidem in liver and renal insufficiency.

G M Pacifici1, A Viani, G Rizzo, M Carrai, J Ganansia, G Bianchetti, P L Morselli.   

Abstract

Similar degree (65-66%) of binding of zolpidem (0.1 microgram/ml) was found with physiological concentrations of isolated human albumin (40 g/l) or alpha-1-acid glycoprotein (1 g/l). Zolpidem binding was studied in plasma from 6 healthy subjects, 12 patients with renal failure, 12 patients with liver cirrhosis and 12 chronic uremics maintained on hemodialysis as well as in 12 serum samples from the placental cord. The unbound fraction (mean +/- s.e.m.) was 8.1 +/- 0.2% (healthy volunteers), 10.8 +/- 0.4% (renal failure), 11.3 +/- 0.7% (liver cirrhosis); 14.9 +/- 1.0% (before hemodialysis); 9.8 +/- 0.4% (after hemodialysis) and 13.2 +/- 0.9% (placental cord). All values, except those after hemodialysis, were significantly different (Dunnett's test) from those of the volunteers. Hemodialysis significantly increased the binding of zolpidem in plasma. The kinetics of protein binding of zolpidem were investigated in plasma samples from 3 healthy subjects. The average number of binding sites was 1.83 x 10(-7) mol per gram protein and the average association constant was 4.49 x 10(5) M-1.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3198298

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  6 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects.

Authors:  Wiesław J Cubała; Jerzy Landowski; Hubert M Wichowicz
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335

3.  Plasma protein binding of alpidem in healthy volunteers, in neonates and in liver or renal insufficiency.

Authors:  G M Pacifici; G Bianchetti; A Viani; G Rizzo; M Carrai; J Allen; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.

Authors:  H D Langtry; P Benfield
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 5.  Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.

Authors:  David R Drover
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications.

Authors:  P Salvà; J Costa
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.